Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
Driven primarily by continued uptake of Shire's market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shire's Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008. ( http://www.bharatbook.com/Market-Research-Reports/Forecast-Insight-Attention-Deficit-Hyperactivity-Disorder-Shire-to-stay-on-top-despite-drug-safety-fears-and-generic-competition.html )
Scope of this research
This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
Provides a global market snapshot by including sales analysis for leading ADHD brands outside the seven major markets.
Key conclusions are supported by key opinion leader comment.
Research and analysis highlights
The April 2009 launch of generic competition in the US will cause sales of Shire's leading ADHD product, Adderall XR, to decline sharply. However, it maintains the expectation that Shire will remain the dominant player in the ADHD market over the forecast period due to the company's broad portfolio of products.
Intuniv (guanfacine hydrochloride) represents Shire's first venture into the non-stimulant segment of the ADHD market. It believes Shire will market Intuniv as a second-line treatment option, due to clinical data demonstrating inferior efficacy to stimulant treatments, putting it in direct competition with Strattera.
The publication of a US government-sponsored study reporting an association between ADHD treatments and sudden unexplained death among pediatrics will reignite the debate over the safety of ADHD drugs in children. The media coverage will cause some parents in the US to choose to discontinue or not begin stimulant therapy for their children.
Key reasons to purchase this research
Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2009 to 2018.
Quantify the current size of the seven major markets and the trends in the rest of the world.
Assess the impact of events, such as patent expiries and new product launches, on the future sales of key brand name ADHD products.
To know more and to buy a copy of your report feel free to visit : ( http://www.bharatbook.com/Market-Research-Reports/Forecast-Insight-Attention-Deficit-Hyperactivity-Disorder-Shire-to-stay-on-top-despite-drug-safety-fears-and-generic-competition.html )
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com |
